SLC5A2 and type 2 diabetes mellitus: Several SGLT2 inhibitors, including canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and bexagliflozin have been approved by the FDA for type 2 diabetes since 2013 (Basak et al., 2023).